FENC
Fennec Pharmaceuticals Inc
10.40$
-2.5%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.6% | 100.0% | 98.5% | 98.4% | 98.4% | 98.2% | 92.6% | 90.9% | 93.5% | 95.0% | 93.1% | 95.7% | |
| 65.2% | 49.4% | 74.0% | 68.2% | 68.4% | 59.3% | 48.9% | 41.7% | 44.6% | 52.1% | 55.9% | 54.5% | |
| 65.2% | 49.4% | 74.0% | 68.2% | 68.4% | 59.3% | 48.9% | 41.7% | 44.6% | 52.1% | 55.9% | 54.5% | |
| 23.8% | 32.8% | 14.8% | 19.5% | 21.9% | 28.7% | 33.3% | 39.0% | 39.3% | 32.9% | 26.1% | 30.7% | |
| 9.2% | 8.0% | 3.0% | 3.4% | 1.9% | 2.4% | 3.0% | 4.9% | 5.0% | 2.2% | 2.6% | 3.1% | |
| 155.3% | 143.3% | 95.6% | 102.1% | 108.8% | 113.1% | 112.7% | 116.6% | 109.1% | 49.7% | 47.5% | 44.0% | |
| 20.6% | 28.1% | 14.2% | 12.3% | 12.6% | 15.4% | 18.0% | 18.7% | 19.9% | 14.9% | 13.3% | 16.4% | |
| 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 15.5% | 14.1% | 7.5% | 7.0% | 6.6% | 7.2% | 11.4% | 13.2% | 11.9% | 6.6% | 8.7% | 7.3% | |
| 134.7% | 115.1% | 45.3% | 50.3% | 54.5% | 43.0% | 41.7% | 43.2% | 39.3% | – | – | – | |
| -55.3% | -43.3% | 4.4% | -2.1% | -8.8% | -13.1% | -12.7% | -16.6% | -9.1% | 50.3% | 52.5% | 56.0% | |
| -1,138.1% | -816.1% | -298.3% | -335.6% | -369.5% | -488.8% | -475.9% | -499.1% | -456.0% | -325.2% | -319.2% | -300.0% | |
| 139.8% | 99.9% | 44.9% | 43.2% | 46.5% | 61.1% | 59.4% | 61.6% | 56.6% | 44.2% | 49.5% | 48.1% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.